We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PARP inhibitors stumble in breast cancer.
- Authors
Guha, Malini
- Abstract
The article focuses on the failure of iniparib, inhibitor of the deoxyribonucleic acid (DNA) repair enzyme poly-adenosine diphosphate (ADP) ribose polymerase (PARP), in its first phase 3 trial for the treatment of metastatic, triple-negative breast cancer (TNBC). Announcements released by pharmaceutical firm Sanofi-Aventis on January 2011 indicate that the PARP inhibitor was not able to prolong survival. It adds that the failure of iniparib urged pharmaceutical firm AstraZeneca to discontinue its phase 3 development of olaparib, another PARP inhibitor.
- Subjects
DNA ligases; ADENOSINE diphosphate; BREAST cancer treatment; SANOFI-Aventis SA; ASTRAZENECA PLC
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 5, p373
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0511-373